Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Income from Continuing Operations came in at 56613000.0 in Q1 2026, down 302.2% YoY from 27999177.4 in Q1 2025, and down 94.78% on a QoQ basis from 29065186.0 in Q4 2025.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Income from Continuing Operations data on file, last reported at 56613000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 302.2% year-over-year to 56613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 108306186.0 (down 58.92% YoY) and the FY2025 annual result came in at 65769186.0, up 18.74% from the prior year.
- Income from Continuing Operations fell to 56613000.0 in Q1 2026, from 29065186.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 118642000.0 in Q4 2022 to a low of 56613000.0 in Q1 2026.
- A 5-year average of 13087305.06 and a median of 17166000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 413.74% — and 2026, when it slumped 302.2%.
- Tracing ARCT's Income from Continuing Operations over 5 years: stood at 118642000.0 in 2022, then slumped by 109.87% to 11707000.0 in 2023, then sank by 156.3% to 30005000.0 in 2024, then gained by 3.13% to 29065186.0 in 2025, then plunged by 94.78% to 56613000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 56613000.0 (Q1 2026), 29065186.0 (Q4 2025), and 13448000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | -23.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.79 Mn |
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -29.07 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.17 Mn |
| Mar 31, 2024 | -26.85 Mn |
| Dec 31, 2023 | -11.68 Mn |
| Sep 30, 2023 | -16.23 Mn |
| Jun 30, 2023 | -52.57 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 118.64 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.27 Mn |
| Dec 31, 2021 | -37.65 Mn |
| Sep 30, 2021 | -53.82 Mn |